v3.26.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Operating activities    
Net loss $ (92,059) $ (103,941)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 8,376 9,838
Stock-based compensation 10,145 19,396
Accretion and amortization of premiums and discounts on investments, net (2,258) (2,725)
Deferred revenue (381) (389)
Change in fair value of stock price appreciation milestones 509 (117)
Loss on disposal of property and equipment 0 (36)
Changes in operating assets and liabilities:    
Accounts receivable 437 2,857
Prepaid expenses and other assets (515) 4,165
Accounts payable and accrued expenses (4,645) (9,892)
Right-of-use assets and lease liabilities, net (1,758) (1,926)
Net cash used in operating activities (82,149) (82,770)
Investing activities    
Proceeds from sale of property and equipment 0 125
Purchases of property and equipment (319) (4,761)
Purchases of investments (104,738) (157,412)
Maturities of investments 170,036 245,584
Net cash provided by investing activities 64,979 83,536
Financing activities    
Issuance of common stock in connection with at-the-market offering, net of commissions and issuance costs 7,598 0
Issuance of common stock from equity incentive plans, net of issuance costs 435 0
Proceeds from FT819-102 CIRM award 1,324 0
Proceeds from FT836 CIRM award 0 3,800
Net cash provided by financing activities 9,357 3,800
Net change in cash, cash equivalents and restricted cash (7,813) 4,566
Cash, cash equivalents and restricted cash at beginning of the period 56,855 46,283
Cash, cash equivalents and restricted cash at end of the period 49,042 50,849
Supplemental schedule of noncash investing and financing activities    
Purchases of property and equipment in accounts payable $ 37 $ 398